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Abstract
Staphylococcus aureus is the most ubiquitous microorganism in both environment 
as well as animals and exists as commensal and pathogenic bacterium. In past few 
years it has been emerged as a superbug causing serious burden on healthcare  
system. This bacterium has been found to be the most resistant one toward most of 
the antibiotics due to its rapid structural and genetic modifications. This chapter 
will shed light on various types of molecular mechanisms responsible for resis-
tance of Staphylococcus aureus showcasing how it has been emerged as a superbug. 
Moreover, the recent approaches which include exploring of different drug targets 
keeping in view the structural and functional behavior of the Staphylococcus aureus 
has also been discussed.
Keywords: Antimicrobial resistance, Staphylococcus aureus, Superbug, Resistance 
Mechanism, Drug resistance, Bacterial resistance
1. Introduction
Staphylococcus aureus is a Gram-positive, catalase and coagulase positive strain of 
bacteria belongs to Micrococcaceae family. Staphylococcus spp. to which these bac-
teria belong is commonly found in nature and human flora. Staphylococcus aureus is 
generally isolated from community as well as hospital gained infections and have 
capability to cause superficial to life threatening infections [1–3]. However, the 
worst scenario in field of microbiology was observed in late 90’s when resistance 
among several microbes including Staphylococcus aureus was reported for various 
antibiotics. Staphylococcus aureus was the most prominent threat among all other 
pathogens due to the rapid emergence of resistance in it. The inappropriate use of 
antimicrobials in clinical therapy and agriculture, extensive antimicrobial con-
sumption and transfer of antimicrobial resistant genes due to increased anthropo-
genic activity are potential risk factors for development of antimicrobial resistance 




Mechanistic insight of quorum sensing in Staphylococcus aureus.
in Staphylococcus aureus [4–6]. Moreover, the intrinsic virulence of Staphylococcus 
aureus, its nature to adapt to the corresponding environment are some other factors 
which makes it the foremost challenge for microbiology scientists. Even though, 
many potential therapeutics have been synthesized/approved by USFDA for the 
treatment of Staphylococcus infections but unfortunately besides this the mortal-
ity rate of Staphylococcus bacteraemia is 20-40% [7–9]. Furthermore, the clinical 
sample (blood samples) of patients with nosocomial infections/staphylococcus 
infections were investigated which confirmed the resistant strains of Staphylococcus 
aureus against various antibiotics that include first- and second-generation fluro-
quinolones, β-Lactam antibiotics, trimethoprim sulphamethoxazole and vancomy-
cin etc. [7, 10, 11]. Surprisingly, the number of antibiotics emerging for treatment 
of this bacteria is directly proportionate to the rapidly evolving resistance mecha-
nisms within Staphylococcus aureus to combat the therapeutic efficacy of these 
antibiotics. In year of 2002-2003 Staphylococcus aureus was found resistant to the 
highly efficient antibiotic vancomycin which left the physicians with no competent 
antibiotic for its treatment. Subsequently it urged the need to explore more drug 
targets and novel approaches for new antibiotics to treat staphylococcus infections. 
Conclusively, the rapid structural and genetic modifications of Staphylococcus 
aureus counterbalance the effect of even magnificent antibiotics. Therefore, 
various molecular mechanisms of Staphylococcus aureus have been deeply explored 
in the recent past to overcome the life-threatening implications of this resistant 
bacteria [12, 13]. This chapter enlightens the historical evolution of resistance in 
Staphylococcus aureus, molecular mechanism of resistance for various antibiotics 
and the modified approaches for its treatment.
2. Quorum sensing in Staphylococcus aureus
Quorum sensing is a well-known phenomenon used mainly by prokaryotes for 
communication among themselves [14]. Particularly in bacteria quorum sensing is 
monitored by a set of signaling molecules called autoinducers as density dependent 
variables. They are released by bacteria around their surrounding environment 
which up on reaching at particular concentration develop a well-coordinated 
response. Density of autoinducers is monitored by bacteria for tracking changes 
in cell number and to alter the gene expression pattern. This is also a factor that 
is responsible for resistance of bacteria against antibiotics [15, 16]. Quorum sens-
ing in Staphylococcus aureus has been coordinated through modified oligopeptide 
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known as autoinducing peptide (AID). In the pathophysiology of Staphylococcus 
aureus regarding quorum sensing, biphasic mechanism exist. At lower cell density, 
Staphylococcus aureus generally express protein factors i.e. Coagulase and fibro-
nectin binding proteins A and B etc. which promote their attachment as well as 
colonization while at higher cellular density Staphylococcus aureus repress these 
traits and initiate secretion of toxins and proteases that needed for dissemination. 
The switching of this gene expression is controlled by Agr quorum sensing system 
that consist of autoinducing peptide (AID) encoded by agrD and two other sensor 
kinase-response regulators called AgrC and AgrA (Figure 1) [17–19].
3.  Various resistance mechanisms of different classes of antibiotics in 
Staphylococcus aureus
3.1 Resistance to β-lactam antibiotics
In early 1940’s introduction of penicillin improved the outcome cases due 
to Staphylococcus infections but soon penicillin resistance Staphylococcus were 
recognized in early 1942 [20] which among late 1960’s reaches to 80% in both 
community and hospital-acquired staphylococcal isolates with well-established 
pattern of resistance [21]. Furthermore, blaZ gene is responsible for resistance in 
Staphylococcus aureus, that encodes for β-lactamase an enzyme which is synthesized 
when Staphylococcus aureus is exposed to β-lactam antibiotics by hydrolyzing the 
β-lactam ring, rendering the β-lactam inactive. blaZ is regulated by the two adjacent 
genes blaR1 and blaI. The gene blaR1 is anti-repressor and blaI is repressor [22]. 
For the synthesis of β-lactamase, the signaling pathway involves the sequential 
cleavage of these regulatory proteins such as blaR1 and blaI where on exposure to 
β-lactams, blaR1 which is a transmembrane sensor transducer cleaves itself [23, 24], 
cleaved protein acts as protease that directly or indirectly cleaves the repressor blaI 
and thus allowing the blaZ to synthesize enzyme [23]. Furthermore, Methicillin, 
the first semisynthetic penicillin which was resistance to penicillinase, introduced 
in 1961 and soon followed by the reporting of methicillin-resistance isolates [25]. 
The spread of Methicillin-resistant Staphylococcus aureus (MRSA) has been critical 
and the infections resulting from MRSA is worse than the infections outcome of 
methicillin ensitive strains [26]. MRSA isolates like the penicillin resistance strains 
too carried resistance genes for other antimicrobial agents [27]. For the resistance 
to methicillin, requires chromosomally localized mecA gene [28, 29], which is a 
part of large unique mobile genetic element, SCC mec found in all MRSA strains 
may contain additional genes for antimicrobial resistance [30, 31] is responsible 
for the synthesis of PBP2a/PBP2′ a 78-kDa protein which binds to penicillin 
(penicillin-binding protein 2a) [32–34]. Transpeptidation which is necessary for 
the cross-linkage of peptidoglycan chains is catalyzed by these membranes bound 
enzymes-PBPs, thought to have appeared and works similar as serine proteases. 
PBP2a blocks the binding of all β-lactams but allows transpeptidation and because 
of its low affinity it allows staphylococci to survive even in the high concentration 
exposure of β-lactam antibiotics. Isolates Resistance to methicillin shows resistance 
to all β-lactam agents, including cephalosporins [34–36]. In some MRSA strains its 
resistance mechanism by mecA via the mecI and mecR1 genes is regulated in the 
manner similar to the regulation of blaZ by the genes blaR1 and blaI when exposed 
to penicillin [37]. Fem genes (factor essential for resistance to methicillin resis-
tance, also play a role in cross-linking the peptidoglycan strands and contribute in 
methicillin resistance [38]. Ceftaroline the fifth-generation cephalosporin accord-
ing to the U.S. Food and Drug Administration (FDA) in 2010 has been considered 
Staphylococcus aureus
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superior among other comparator drugs for the treatment of complicated skin and 
soft tissue infections as well as pneumonia [39]. β -lactam antibiotics bind to other 
PBPs, named PBP1, −2, −3, and − 4 but in the presence of PBP2a they are unable 
to bind effectively to their PBP targets. Ceftaroline on other hand is active against 
MRSA strains because of its high binding affinity for PBP2a as comparison to other 
β -lactam [40]. Binding of PBPs by ceftaroline block these enzymes to catalyze the 
transpeptidase function that is important for the synthesis of staphylococcal cell 
wall [41]. Ceftaroline is generally considered safe and successfully used to treat 
wide infections alone and in combination with other active drugs often with dapto-
mycin [42]. Several studied over MRSA clinal strains showed these were susceptible 
to ceftaroline in wide range such as >98.4% in North America [43], >83.3% in Latin 
America [44], >83% in Europe [45], 78.8% in Asia/South Pacific countries [46] the 
variation in resistance among MRSA may be due to the variation in geographical 
distribution of strains around the world [47, 48]. MRSA strains carry mobile genetic 
element known as SCCmec, which carries mecA gene [40]. Ceftaroline resistance 
is usually due to the nonsense mutations in mecA, resulting in amino acid sequence 
change in PBP2a hence a target protein mutation [49]. Glu447Lys mutation in 
mecA in presence of ceftaroline on SF8300 USA300 MRSA strain yields low level 
resistance isolates whereas COL common laboratory strain showed high ceftaroline 
resistance due to mutations in pbp2, pbp4 and gdpP not due to mecA [50]. There are 
strains developing resistance with no change in mecA [51].
3.2 Resistance to vancomycin
Vancomycin, a lipopeptide antibiotic approved by Food and Drug 
Administration of the United States in 1958 found in recent years that the MRSA 
isolates are resist to it [52]. Vancomycin works by binding to bacterial cell envelopes 
and inhibiting their cell wall synthesis instead of targeting protein like other antibi-
otics [53]. It binds to C-terminal D-Ala–D-Ala residue of the pentapeptide to inhibit 
the cross-bridge formation between pentapeptide and pentaglycine preventing cell 
wall synthesis [54]. MRSA strains shows different ranges of resistance against van-
comycin according to their MIC and are named accordingly such as MRSA showing 
complete resistance to vancomycin is termed vancomycin-resistant Staphylococcus 
aureus (VRSA), showing medium resistance is termed as vancomycin intermediate-
resistant Staphylococcus aureus (VISA) and least resistance as VSSA [55].
Failure in vancomycin treatment of MRSA results due to formation of 
intermediate-resistant isolates namely hetero resistant vancomycin-intermediate 
Staphylococcus aureus (hVISA) and vancomycin intermediate Staphylococcus aureus 
(VISA) [56] which includes features such as cell wall thickening, reduced autolytic 
activit and reduced growth rates [57]. Several studies found that the mutation in 
genes VraS(S329L), MsrR(E146K), GraR(N197S), RpoB(H481Y), Fdh2(A297V) 
and Sle1(67aa) were also responsible for vancomycin resistance in VISA strain 
Mu50 [58]. Other genes involving in high- and low-level resistance to vancomycin 
includes vanA, vanB, vanD, vanF, vanI, vanM, encodes for D-Ala:D-Lac ligases 
whereas vanC, vanE, vanG, vanL, and vanNgenes encoding D-Ala:D-Ser ligases 
(Figure 2) [59, 60].
3.3 Resistance to lipopeptide based antibiotic daptomycin
The only approved and available lipopeptide in the US in the year 2003 with 
in vitro bactericidal activity and an alternative to vancomycin for various MRSA 
infections, is daptomycin [61]. However, during the treatment, the emergence of 
non-susceptible MRSA strains for daptomycin has been reported [62, 63]. Even 
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before the approval of drug, Silverman et al. observed daptomycin non-susceptible 
mutants and identified number of changes such as increase in membrane fluid-
ity, increase in net positive charge over the surface, decrease in susceptibility to 
daptomycin-induced depolarization and low in surface binding of daptomycin in 
the cytoplasmic membrane of non-susceptible strains [64, 65]. Though the basis 
for reduction in susceptibility to daptomycin in MRSA strains has not been fully 
clarified [66]. The transfer and addition of positively charged lysine molecules to 
phosphatidyl glycerol in the cell membrane associated with the activity of enzyme 
lysyl-phosphatidyl glycerol synthetase is encoded by mprF gene [67], Mutation 
in mprF gene causes an increase of lysyl-phosphatidyl glycerol in the outer layer 
of the cell membrane, leading to an increased positive charge resulting in reduced 
susceptibility to daptomycin [68]. mprF mutations are the most common type of 
mutation in MRSA strains with reduced susceptibility to daptomycin (Figure 3) 
[69]. Several more genes are also identified which are associated with the reduced 
susceptibility to daptomycin such as dsp1 or asp23. The inactivation of these genes 
leads to reduced daptomycin susceptibility and the overexpression of single or both 
of the genes leads increase in susceptibility [70] whereas expression of dltA gene 
contributes to the staphylococcal net positive surface charge [71]. Kanesaka et al. 
using transmission electron microscopy, found that the some of the strains which 
were exposed to daptomycin which shows resistance developed an increase in the 
thickness of their cell wall and their thickness decreases on revert to daptomycin 
susceptible [72].
3.4 Resistance to aminoglycosides
Aminoglycosides works by mistranslation and changing the conformation of 
tRNA during bacterial protein synthesis by binding to A-site present on 16S rRNA 
of the 30S ribosome. Some even acts by inhibiting initiation /or elongation phase 
thereby blocking bacterial protein synthesis [73]. Most common mechanism of resis-
tance to aminoglycosides especially in Staphylococcus aureus includes Aminoglycoside 
modifying enzymes which works by acetylating, phosphorylating, or adenylating 
amino or hydroxyl groups therefore inactivating aminoglycosides. Hundreds of 
aminoglycosides modifying enzymes are known encoded by genes which are com-
monly found on plasmids and transposons [74]. On clinical practising with some 
Figure 2. 
Molecular mechanism of Staphylococcus aureus resistance toward penicillin and vancomycin.
Staphylococcus aureus
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aminoglycosides such as gentamicin, tobramycin, and amikacin these three among 
Aminoglycoside modifying enzymes such as ANT(4=) nucleotide transferase, 
bidomain AAC(6=)le-APH(2=)la acetyltransferase and phosphotransferase, and 
APH(3=)IIIa phosphotransferase which are common in MRSA isolates with varied 
appearance, shows resistance [75]. Plazomicin, a synthetic aminoglycoside showed in 
vitro activity against 55 MRSA isolates that expressed one or more aminoglycoside-
modifying enzymes [76] and has no protection against other resistance mechanism 
such as 16 s rRNA methyltransferases that modifies the aminoglycoside target site 
but these enzymes are not reported in S. aureus (Figure 4) [77].
3.5 Resistance to oxazolidinones
Oxazolidinones, the synthetic antibiotics blocks the formation of functional 
70S initiation complex thereby preventing bacterial protein synthesis. Linezolid 
and tedizolid types of drugs from Oxazolidinones works interrupting transitional 
RNA positioning by binding to the bacterial 23S rRNA at the ribosomal peptide-
transferase center. Even with the similarity in both of the structure tedizolid still 
Figure 3. 
Molecular mechanism of Staphylococcus aureus resistance toward daptomycin via mprF.
Figure 4. 
Molecular mechanism of Staphylococcus aureus resistance toward aminoglycosides.
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shows increased and better interactions at the binding site with increased potency 
[78]. All these resistance mechanisms make alteration to oxazolidinone binding 
site, most common are the point mutations occurring in the genes encoding for 23S 
rRNA mostly in the central loop of domain V [79]. S. aureus has four to seven copies 
of 23S rRNA gene collection of which determines the effect and degree of linezolid 
resistance [80, 81]. This kind of mutation, G2576T, in all five copies of its 23S rRNA 
gene has been found in the first clinical isolates of linezolid-resistant MRSA [82] are 
most common. Mutations in the genes which are encoding for L3 and L4 similar to 
mutation in 23S rRNA, induces a change in the linezolid binding site shows linezolid 
resistance. Studies showed structural rearrangement of the linezolid binding site due 
to deletion of one amino acid in L3 causing change in the position of several of the 
23S rRNA bases as targeted by point mutations. Gene cfr (chloramphenicol-florfen-
icol resistance) linked with various mobile genetic elements also shows resistance to 
linezolid and other antibiotics by change in the drug binding site at the ribosomal 
peptide-transferase center by encoding a rRNA methyltransferase that causes change 
in position A2503 [83–85]. Several bacterial species port the cfr gene, a reservoir 
for drug resistance. MRSA isolates with cfr genes are more likely have additional 
antibiotic resistance genes as compared to non-cfr gene isolates. Another gene, optrA 
found commonly symbiosis with cfr gene in MRSA isolates also shows resistance to 
oxazolidinones [84]. Acts as an ATP-binding cassette transporter, which mediate 
the influx and efflux of drugs. Another optrA structurally similar gene poxtA first 
identified in MRSA isolates, shows in vitro resistance to oxazolones [86–89].
3.6 Resistance to quinolones with a focus on novel antibiotic delafloxacin
The fluoroquinolones (FQ ) were first introduced into clinical practice in the 
year 1962 along with the development of Nalidixic acid. Fluoroquinolones (FQ ) are 
class of fully synthetic antibiotics which are active against a broad range of gram 
positive and gram-negative bacteria and have a pivotal role in multidrug resistance 
therapy in Mycobacterial infection (Tuberculosis and non-tuberculosis). To treat 
acute bacterial skin and skin structure infections (ABSSSIs) with both enteral 
and intravenous preparations FDA approved non zwitter ionic FQ delafloxacin 
in 2017 [90]. Due slower MICs against S. aureus than other FQs delafloxacin has a 
higher barrier to resistance, it can serve as ant staphylococcal drug as monotherapy. 
Delafloxacin is found to be effective against multiple like Streptococcus pneu-
moniae, anaerobic bacteria Legionella, Chlamydia pneumoniae, Neisseria gonor-
rhoeae, Mycoplasma spp., in addition to Staphylococcus aureus. Its activity against 
the enterococci is variable [91]. Delafloxacin shows a property of “dual-targeting” 
in which it can form complexes with DNA and topoisomerase IV or DNA gyrase. 
Double strand break can be produced by the inhibiting the one or both the enzymes 
which results in the death of bacterial cell as they lack enzymes that can repair 
double strand break in DNA. Delafloxacin shows more potency against Gram posi-
tive bacteria as it shows anionic behavior at neutral pH due to the substitution of the 
R7 position (3-hydroxy-1-azetidinyl) [90, 92]. An anionic behavior of delafloxacin 
makes diffusion and accumulation of drug within the bacteria more readily as it 
is retained in bacterial cell for longer duration at neutral intracellular pH [93]. 
These characteristics makes antibiotics more effective in acidic environments [94]. 
Depending upon the ambient pH it shows activity against biofilm related infections 
and intracellular infections [91]. Estimated concentration of Delafloxacin select-
ing resistant mutant is 8 to 32 times lesser than for other Fluoroquinolones. This 
difference is due to the drugs dual targeting mechanism of action. Point mutations 
are method by which resistance is shown by bacteria, resistance occurs due to point 
mutations in target enzyme or by the action of efflux pump. Point mutation in ParC 
Staphylococcus aureus
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subunit of topoisomerase IV results in resistance in case of Staphylococcus aureus. 
Delfatoxin resistance occurs due to various mutations in the target regions of topoi-
somerase IV [92–95]. Resistance to the FQs, including delafloxacin, often involves 
point mutations in the target enzymes or the action of efflux pumps in bacterial 
cells. In S. aureus, resistance is usually mediated by point mutations in the ParC 
subunit of topoisomerase IV. Delafloxacin often retains potency against S. aureus 
resistant to other FQ drugs due to target gene mutations or modifications. This rela-
tive resistance seems related to the structure of delafloxacin (perhaps due to C-7 and 
C-8 substitutions); delafloxacin resistance occurs only with several mutations in 
the target regions of topoisomerase IV. NorA, NorB, NorC, MdeA, QacA, and QacB 
includes a resistant phenotype of Common S. aureus efflux pumps active against 
Fluoroquinolones. The antiseptic chlorhexidine gluconate is also removed from cells 
by the plasmid-encoded efflux pumps QacA and QacB, sometimes called antiseptic 
resistance genes and their acquisition in a S. aureus population is co-selected by 
use of chlorhexidine or FQs. Delafloxacin is not as active substrate for typical 
Staphylococcus aureus efflux pumps compared to other drugs in the class [96–99].
3.7 Resistance to new class of antibiotics: pleuromutilins
In 1951 a compound Pleuromutilin a class of antibacterial which is isolated from 
a fungus called Pleurotomariids. Pleuromutilin and its natural molecule found to 
be effective against Gram-positive bacteria. For veterinary use Tiamulin used in 
livestock for the treatment of gastrointestinal and respiratory disease. Valnemulin is 
a second veterinary systemic Pleuromutilin antimicrobial approves and widely use in 
Asia and Europe. For systemic human use lefamulin was synthesized in 2006, lefam-
ulin is novel pleuromutilin drug effective against most MRSA strains [100]. In phase 
2 lefamulin was non inferior to intravenous Vancomycin. Pleuromutilin interferes 
with the process of protein synthesis by inhibiting the 50s subunit of the ribosome 
binding at site called peptidyl transfer centre [101, 102]. They specifically target the 
inhibition of initiation of translation. The extensive use of tiamulin and valenemulin 
for decades in livestock leads to MRSA strains and their mechanism of resistance to 
pleuromutilin are well studied. One of the resistance mechanisms involves alteration 
of target site on the ribosome which may require three or more mutations to develop 
resistant phenotype [103–105]. Resistant clones may be formed when Staphylococcus 
aureus acquire new genes by horizontal gene transfer including transferable cfr 
gene methylation a specific site on 23S rRNA. This methylation by cfr gene product 
results in resistance to several class of antibiotics including pleuromutilin, linezolid, 
streptogramin, phenicol, and lincosamides. In S. aureus is the family of at least four 
vga genes with variants, including vga(A)v, vga(A), vga(C), and vga(E), as well as 
lsa(E), all result in ribosomal protection results in cause of pleuromutilin resistance 
in S. aureus. Plasmid or transposons can carry strains vga(A) may become transmis-
sible among strains. In ST398 livestock-associated MRSA strains found vga(c) strain 
also be carried on plasmid. The spread of mobile genetic elements among animal and 
human S. aureus strains raises concern for the emergence of widespread pleuromuti-
lin resistance among human strains if drugs in this class are widely used [106, 107].
3.8 Resistance to mupirocin
Mupirocin was used as a decolonizing agent. It is widely used in CA-MRSA 
epidemic United States in 1990. But it was discovered in in 1970. Resistance to 
mupirocin by MRSA developed [10, 108]. Mupirocin resistance is developed due to 
ileS-2 gene [109]. The mupA and mupB genes responsible for resistance to mupiro-
cin these genes encode novel isoleucyl-tRNA synthetases and can be carried out by 
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plasmids [110]. The threes aspect of REDUCE-MRSA study was cluster-randomized 
trial that evaluate screening, isolation, and decolonization with chlorhexidine and 
mupirocin in intensive care unit patients [111]. Mupirocin is best suitable option 
for MRSA nasal decolonization but shows some side effects. Development of novel 
decolonization agent should be our propriety. We can also develop agents that can 
act synergistically with mupirocin as recently described [112, 113].
3.9 Resistance to lipoglycopeptides
Dalbavancin, oritavancin, and telavancin, the semisynthetic derivatives of 
glycopeptides are the three lipoglycopeptides available in the US. Glycopeptides usu-
ally inhibits bacterial cell wall synthesis by binding to D-alanyl-D-alanine (D-Ala-
D-Ala) terminal of growing peptidoglycan chains [114]. Due to their distinctiveness 
in structural modifications of each drugs heptapeptide core, lipoglycopeptides are 
more powerful than vancomycin which contains lipid side chain that helps in holding 
the drug to cell membrane providing stability and an increase in concentration of 
local drug. In case of oritavancin and telavancin their interaction with the cell wall 
promotes another mechanism of action as concentration-dependent depolarization 
of cell membrane leading to increase in permeability. Because of the structure of 
oritavancin it allows several other mechanisms of action which includes binding to 
the secondary site in peptidoglycan chains, pentaglycyl bridging segment of lipid II, 
transpeptidation inhibition and RNA synthesis inhibition [115, 116]. A survey study 
conducted from 2010 to 2014 in US and Europe showed 99.9% isolates of S. aureus 
susceptible to oritavancin and 98% isolates susceptible to dalbavancin in global sur-
vey during 2002 to 2012 [117] with rare Lipoglycopeptide resistance among S. aureus. 
Recently for dalbavancin, Resistance in some clinical isolates has been reported. On 
structural analysis showed an increase in the thickening of cell wall and abnormal 
cell wall construction in dalbavancin non-susceptible isolates [118, 119].
4. Evolution of Staphylococcus aureus as superbug
Alexander Flaming accidently discovered penicillin as fungal contaminant also 
having bactericidal effect against Staphylococcus aureus which in turn led to bulk 
production of this antibiotic [120]. Consequently, death rate due to bacterial pneu-
monia and meningitis fell down during World War II. Penicillin was discovered to 
act by breaking peptidoglycan assembly within bacterial cell wall followed by cell 
death due to osmotic fragility [121]. In early 1940’s death rate of Staphylococcal 
infections was approximately 80%. However, resistance Staphylococcus aureus 
strains were observed after overuse of penicillin which got predominant in 1945 
[122–124]. The major cause of this resistance was the eventual formation of plasmid 
encoded-lactamase which found to have ability of hydrolysing active moiety i.e. 
lactam ring of penicillin [124, 125]. The ability of plasmid encoded-lactamase to 
readily transfer which rises the penicillin against bacterial resistance rate up to 
90-95%. Moreover, in 1950 a resistant clone of Staphylococcus aureus called phage 
80/81 was responsible for the outbreak pandemic of skin infections, sepsis of skin 
and pneumonia. Initially it was concerned inside the premises of hospital but even-
tually it outspread within the public outside [126]. Australia, America and Canada 
were the majorly effected countries during this epidemic which lasted for almost 
10 years until a methicillin came into market [127]. It was purposely designed in 
1959 for the lactamase resistance strains of staphylococci and their treatment but 
surprisingly it worked efficiently for only one year because later on the methicil-
lin resistance strain of Staphylococcus aureus was first observed in 1961 in United 
Staphylococcus aureus
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Kingdom [128]. The major cause of acquired resistance was mecA gene at specific 
site of chromosome. mecA gene was reported to encode an alternative penicillin 
binding protein gene called PBR2a and PBR2 which possessed very little binding 
affinity against penicillin, methicillin, nafcillin and cephem derivatives [129]. 
However, this resistance was found to be different from penicillin acquired resis-
tance as it included broad spectrum antibiotics i.e. almost entire class of lactams 
except ceftaroline and ceftobiprole [130]. Adding on, a genetic element was found 
to be the prime carrier of mecA gene and was responsible for the broad-spectrum 
resistance as well as outbreak of its infections in 1980 [131]. Few countries that had 
major impact were Ireland, United States and United Kingdom. Despite the fact 
that it was first observed in 1961 it was highly appeared in 1980 and responsible for 
pandemic. MRSA was major risk for people having low immunity therefore death 
rate was approximately 15 times and bacteraemia was observed to be 24-fold than 
earlier [132]. MRSA outspread in Europe in early 1970’s was confirmed to be caused 
by one of the MRSA clones called 83 phages; an archaic clone which eventually 
became demolished and replaced by another five lineage clones of MRSA by 1980’s. 
The foremost MRSA infection case was observed in Sydney in 1965 followed by 
sporadic nosocomial MRSA infections in Melbourne, Sydney and other cities of 
Australia [133, 134]. Western Australia was rather reported to be free from these 
infections until late 1980’s when gentamicin susceptible Non-Multidrug Resistant 
(MDR) MRSA was observed first which later on outspread very fast [135, 136]. 
However, the quickest outbreak of MRSA was observed in Boston, United States 
of America in 1968 [137]. Number of cases increased drastically from 2.4–29% 
from 1968 to 1975 which rose to 56.1% till 2003 [138, 139]. Moreover, high rate of 
MRSA infections was observed in other parts across the world also [140–147]. In 
japan MRSA infections invaded in academic hospitals in 1980 which later become 
community spread in 1990 [148]. Number of MRSA infected patients were com-
paratively lower than observed in America however mild increase was observed 
in frequency of MRSA patients from 3.8% - 9.6% in 1990-1994. But when only the 
outpatients were considered the MRSA infection rate was observed to be drastically 
rose from 4.5-35% in 1994 [149, 150]. The first clinical isolate of MRSA known to 
carry PVL gene in CA-MRSA era was observed in 2003. Furthermore, according to 
the data given by National Infectious disease register in 10-fold increase in MRSA 
infectious cases i.e. 120-1458 has been found in 2004. Meanwhile the countries 
like Norway, Sweden, Denmark and Netherland were found to be free from these 
infections due to strict surveillance. In the period of six years (2000-2006), Eastern 
Australia and Queensland were reported to have an increase of 75-315 patients 
per million. MRSA strains prevalent in these countries were majorly non-MDR 
strains which have susceptibility to ciprofloxacin and resistant at least to one of the 
β-lactams. It was a period of high emergence of non-MDR strains of MRSA. In 2011, 
surveillance studies were carried out in Asian countries to find out the patients with 
MRSA infections [151–154]. Data revealed HA-MRSA prevalence was highest in Sri 
Lanka (86.5%) followed by Vietnam (74.1%), South Korea (65%), Thailand (57%) 
and Hong Kong (56.8%). However, the rate of infections in Indians and Philippines 
was quite low i.e. 22.6 and 38.1% approximately. Infected patients and staff were the 
major reason for the outbreak of MRSA across the countries and continents. With 
time and resistance MRSA had been found to be emerged, declined and modified 
accordingly. When initially observed, the MRSA strains were confined only to the 
hospitals and health care centres which later on becomes a pandemic via commu-
nity spread. Moreover, livestock was also found to be affected by MRSA infections. 
According to last research report vancomycin was an antibiotic susceptible to MRSA 
however later on some investigations demonstrated Vancomycin Intermediate 
resistance Staphylococcus aureus (VISA) and Vancomycin Resistant Staphylococcus 
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aureus (VRSA) in some clinical strains. If this trend gets continued to be followed 
further then MRSA will undoubtedly become completely resistant strain which is a 
serious topic of concern in field of infectious diseases [155–158].
5. Conclusion
The rapid evolution of resistance in Staphylococcus aureus toward almost every 
antibiotic makes it a most challenging threat for human health as well as for the 
microbiology scientists. This bacteraemia has been reported to possess resistance 
mechanisms on the exposure of antibiotics only. Staphylococcus aureus quickly 
develop the defense/survival mechanism for even the new antibiotics which 
probably due to their fast structural and genetical alterations. Keeping this in 
view, several novel compounds are in pipeline to combat the resistant strains of 
Staphylococcus aureus. Moreover, identification of additional drug targets, better 
stewardship and combination therapies are also in process for the treatment of 
resistant strains of Staphylococcus aureus.
Acknowledgements
Authors are grateful to the University Grants Commission for providing NFOBC 
to Atamjit Singh. The authors are also thankful to Guru Nanak Dev University, 
Amritsar for providing various facilities to carry out the work.
Conflict of interest
The authors declare no conflict of interest.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
12
Staphylococcus aureus
[1] Ali, E. A., Alshuaibi, O. N., & Ali, K. 
S. (2021). Evaluation of some antibiotic 
resistance in staphylococcus aureus 
isolated by medical laboratories aden, 
yemen. Electronic Journal of University 
of Aden for Basic and Applied Sciences, 
2(1), 49-53.
[2] Rağbetli, C., Parlak, M., Bayram, Y., 
Guducuoglu, H., & Ceylan, N. (2016). 
Evaluation of antimicrobial resistance in 
Staphylococcus aureus isolates by years. 
Interdisciplinary perspectives on 
infectious diseases, 2016.
[3] Ioannou, C. J., Hanlon, G. W., & 
Denyer, S. P. (2007). Action of 
disinfectant quaternary ammonium 
compounds against Staphylococcus 
aureus. Antimicrobial agents and 
chemotherapy, 51(1), 296.C. J. Ioannou,
[4] Cohen, M. L. (1992). Epidemiology 
of drug resistance: implications for a 
post—antimicrobial era. Science, 
257(5073), 1050-1055.
[5] Tomasz, A. (1994). Multiple-
Antibiotic-Resistant Pathogenic 
Bacteria--A Report on the Rockefeller 
University Workshop. New England 
journal of medicine, 330(17), 1247-1251.
[6] Swartz, M. N. (1997). Use of 
antimicrobial agents and drug 
resistance.
[7] Lowy, F. D. (1998). Staphylococcus 
aureus infections. New England journal 
of medicine, 339(8), 520-532.
[8] Mandell, G. L., Bennett, J. E., & 
Dolin, R. (2000). Staphylococcus aureus 
(including Staphylococcal toxic shock). 
Bennett’s-Principles and Practice of 
Infectious Diseases.
[9] Mylotte, J. M., McDermott, C., & 
Spooner, J. A. (1987). Prospective study 
of 114 consecutive episodes of 
Staphylococcus aureus bacteremia. 
Reviews of infectious diseases, 9(5), 
891-907.
[10] Diekema, D. J., Pfaller, M. A., 
Schmitz, F. J., Smayevsky, J., Bell, J., 
Jones, R. N., ... & SENTRY Participants 
Group. (2001). Survey of infections due 
to Staphylococcus species: frequency of 
occurrence and antimicrobial 
susceptibility of isolates collected in the 
United States, Canada, Latin America, 
Europe, and the Western Pacific region 
for the SENTRY Antimicrobial 
Surveillance Program, 1997-1999. 
Clinical Infectious Diseases, 
32(Supplement_2), S114-S132.
[11] Hiramatsu, K., Hanaki, H., Ino, T., 
Yabuta, K., Oguri, T., & Tenover, F. C. 
(1997). Methicillin-resistant 
Staphylococcus aureus clinical strain 
with reduced vancomycin susceptibility. 
The Journal of antimicrobial 
chemotherapy, 40(1), 135-136.
[12] Centers for Disease Control and 
Prevention (CDC. (2002). 
Staphylococcus aureus resistant to 
vancomycin--United States, 2002. 
MMWR. Morbidity and mortality 
weekly report, 51(26), 565-567.
[13] Skinner, D., & Keefer, C. S. (1941). 
Significance of bacteremia caused by 
Staphylococcus aureus: a study of one 
hundred and twenty-two cases and a 
review of the literature concerned with 
experimental infection in animals. 
Archives of internal medicine, 68(5), 
851-875.
[14] Rajput, A., Kaur, K. and Kumar, M., 
2016. SigMol: repertoire of quorum 
sensing signaling molecules in 
prokaryotes. Nucleic acids research, 
44(D1), D634-D639.
[15] Waters, C.M. and Bassler, B.L., 
2005. Quorum sensing: cell-to-cell 
communication in bacteria. Annu. Rev. 
Cell Dev. Biol., 21, 319-346.
References
13
Mechanistic Insights of Drug Resistance in Staphylococcus Aureus with Special Reference to Newer…
DOI: http://dx.doi.org/10.5772/intechopen.100045
[16] Papenfort, K. and Bassler, B.L., 
2016. Quorum sensing signal–response 
systems in Gram-negative bacteria. 
Nature Reviews Microbiology, 14(9), 
576-588.
[17] Huang, J., Shi, Y., Zeng, G., Gu, Y., 
Chen, G., Shi, L., Hu, Y., Tang, B. and 
Zhou, J., 2016. Acyl-homoserine 
lactone-based quorum sensing and 
quorum quenching hold promise to 
determine the performance of biological 
wastewater treatments: an overview. 
Chemosphere, 157, 137-151.
[18] Queck, S.Y., Jameson-Lee, M., 
Villaruz, A.E., Bach, T.H.L., Khan, B.A., 
Sturdevant, D.E., Ricklefs, S.M., Li, M. 
and Otto, M., 2008. RNAIII-
independent target gene control by the 
agr quorum-sensing system: insight into 
the evolution of virulence regulation in 
Staphylococcus aureus. Molecular cell, 
32(1), 150-158.
[19] Queck, S.Y., Jameson-Lee, M., 
Villaruz, A.E., Bach, T.H.L., Khan, B.A., 
Sturdevant, D.E., Ricklefs, S.M., Li, M. 
and Otto, M., 2008. RNAIII-
independent target gene control by the 
agr quorum-sensing system: insight into 
the evolution of virulence regulation in 
Staphylococcus aureus. Molecular cell, 
32(1), 150-158.
[20] Rammelkamp, C. H., & Maxon, T. 
(1942). Resistance of Staphylococcus 
aureus to the Action of Penicillin. 
Proceedings of the Society for 
Experimental Biology and Medicine, 
51(3), 386-389.
[21] Chambers, H. F. (2001). The 
changing epidemiology of 
Staphylococcus aureus?. Emerging 
infectious diseases, 7(2), 178.
[22] Kernodle, D. S. (2000). Gram-
positive pathogens. Fischetti, VA, 
609-620.
[23] Gregory, P. D., Lewis, R. A., 
Curnock, S. P., & Dyke, K. G. H. (1997). 
Studies of the repressor (BlaI) of 
β-lactamase synthesis in Staphylococcus 
aureus. Molecular microbiology, 24(5), 
1025-1037.
[24] Zhang, H. Z., Hackbarth, C. J., 
Chansky, K. M., & Chambers, H. F. 
(2001). A proteolytic transmembrane 
signaling pathway and resistance to 
β-lactams in staphylococci. Science, 
291(5510), 1962-1965.
[25] Jevons, M. P. (1961). Letter Br. 
Med J, 1, 124-125.
[26] Cosgrove, S. E., Sakoulas, G., 
Perencevich, E. N., Schwaber, M. J., 
Karchmer, A. W., & Carmeli, Y. (2003). 
Comparison of mortality associated 
with methicillin-resistant and 
methicillin-susceptible Staphylococcus 
aureus bacteremia: a meta-analysis. 
Clinical infectious diseases, 36(1), 53-59.
[27] Lyon, B. R., Iuorio, J. L., May, J. W., 
& Skurray, R. A. (1984). Molecular 
epidemiology of multiresistant 
Staphylococcus aureus in Australian 
hospitals. Journal of medical 
microbiology, 17(1), 79-89.
[28] Kernodle, D. S. (2000). Gram-
positive pathogens. Fischetti, VA, 
609-620.
[29] Chambers, H. F. (1997). Methicillin 
resistance in staphylococci: molecular 
and biochemical basis and clinical 
implications. Clinical microbiology 
reviews, 10(4), 781-791.
[30] Katayama, Y., Ito, T., & Hiramatsu, 
K. (2000). A new class of genetic 
element, staphylococcus cassette 
chromosome mec, encodes methicillin 
resistance in Staphylococcus aureus. 
Antimicrobial agents and 
chemotherapy, 44(6), 1549-1555.
[31] Ito, T., Katayama, Y., & Hiramatsu, 
K. (1999). Cloning and nucleotide 
sequence determination of the entire 
mec DNA of pre-methicillin-resistant 
Staphylococcus aureus
14
Staphylococcus aureus N315. 
Antimicrobial agents and 
chemotherapy, 43(6), 1449-1458.
[32] Hartman, B. J., & Tomasz, A. 
(1984). Low-affinity penicillin-binding 
protein associated with beta-lactam 
resistance in Staphylococcus aureus. 
Journal of bacteriology, 158(2), 513-516.
[33] Utsui, Y. U. K. I. O., & Yokota, T. A. 
K. E. S. H. I. (1985). Role of an altered 
penicillin-binding protein in 
methicillin-and cephem-resistant 
Staphylococcus aureus. Antimicrobial 
agents and chemotherapy, 28(3), 
397-403.
[34] Song, M. D., Wachi, M., Doi, M., 
Ishino, F., & Matsuhashi, M. (1987). 
Evolution of an inducible penicillin-
target protein in methicillin-resistant 
Staphylococcus aureus by gene fusion. 
FEBS letters, 221(1), 167-171.
[35] Ghuysen, J. M. (1994). Molecular 
structures of penicillin-binding proteins 
and β-lactamases. Trends in 
microbiology, 2(10), 372-380.
[36] Lim, D., & Strynadka, N. C. (2002). 
Structural basis for the β lactam 
resistance of PBP2a from methicillin-
resistant Staphylococcus aureus. Nature 
structural biology, 9(11), 870-876.
[37] Archer, G. L., & Bosilevac, J. M. 
(2001). Signaling antibiotic resistance in 
staphylococci. Science, 291(5510), 
1915-1916.
[38] Berger-Bächi, B. (1994). Expression 
of resistance to methicillin. Trends in 
microbiology, 2(10), 389-393.
[39] Saravolatz, L. D., Stein, G. E., & 
Johnson, L. B. (2011). Ceftaroline: a 
novel cephalosporin with activity 
against methicillin-resistant 
Staphylococcus aureus. Clinical 
infectious diseases, 52(9), 1156-1163.
[40] Chung, M., Antignac, A., Kim, C., 
& Tomasz, A. (2008). Comparative 
study of the susceptibilities of major 
epidemic clones of methicillin-resistant 
Staphylococcus aureus to oxacillin and 
to the new broad-spectrum 
cephalosporin ceftobiprole. 
Antimicrobial agents and 
chemotherapy, 52(8), 2709-2717.
[41] Biek, D., Critchley, I. A., Riccobene, 
T. A., & Thye, D. A. (2010). Ceftaroline 
fosamil: a novel broad-spectrum 
cephalosporin with expanded anti-
Gram-positive activity. Journal of 
antimicrobial chemotherapy, 
65(suppl_4), iv9-iv16.
[42] Sakoulas, G., Moise, P. A., Casapao, 
A. M., Nonejuie, P., Olson, J., Okumura, 
C. Y., Rybak, M.J., Kullar, R., Dhand, 
A., Rose, W.E., & Nizet, V. (2014). 
Antimicrobial salvage therapy for 
persistent staphylococcal bacteremia 
using daptomycin plus ceftaroline. 
Clinical therapeutics, 36(10), 
1317-1333.
[43] Sader, H. S., Farrell, D. J., Flamm, R. 
K., & Jones, R. N. (2015). Activity of 
ceftaroline and comparator agents 
tested against Staphylococcus aureus 
from patients with bloodstream 
infections in US medical centres (2009-
13). Journal of Antimicrobial 
Chemotherapy, 70(7), 2053-2056.
[44] Biedenbach, D. J., Hoban, D. J., 
Reiszner, E., Lahiri, S. D., Alm, R. A., 
Sahm, D. F., Bouchillon, S.K., & 
Ambler, J. E. (2015). In vitro activity of 
ceftaroline against Staphylococcus 
aureus isolates collected in 2012 from 
Latin American countries as part of the 
AWARE surveillance program. 
Antimicrobial agents and 
chemotherapy, 59(12), 7873-7877.
[45] Farrell, D. J., Flamm, R. K., Sader, 
H. S., & Jones, R. N. (2013). Spectrum 
and potency of ceftaroline tested against 
leading pathogens causing skin and 
soft-tissue infections in Europe (2010). 
International journal of antimicrobial 
agents, 41(4), 337-342.
15
Mechanistic Insights of Drug Resistance in Staphylococcus Aureus with Special Reference to Newer…
DOI: http://dx.doi.org/10.5772/intechopen.100045
[46] Biedenbach, D. J., Alm, R. A., Lahiri, 
S. D., Reiszner, E., Hoban, D. J., Sahm, 
D. F., Bouchillon, S.K., & Ambler, J. E. 
(2016). In vitro activity of ceftaroline 
against Staphylococcus aureus isolated in 
2012 from Asia-Pacific countries as part 
of the AWARE surveillance program. 
Antimicrobial agents and chemotherapy, 
60(1), 343-347.
[47] Abbott, I. J., Jenney, A. W. J., 
Jeremiah, C. J., Mirčeta, M., Kandiah, J. 
P., Holt, D. C., Tong, S.Y.C., & Spelman, 
D. W. (2015). Reduced in vitro activity 
of ceftaroline by Etest among clonal 
complex 239 methicillin-resistant 
Staphylococcus aureus clinical strains 
from Australia. Antimicrobial agents 
and chemotherapy, 59(12), 7837-7841.
[48] Mubarak, N., Sandaradura, I., Isaia, 
L., O'Sullivan, M., Zhou, F., Marriott, 
D., Iredell, J.R., Harkness, J., & 
Andresen, D. (2015). Non-susceptibility 
to ceftaroline in healthcare-associated 
multiresistant MRSA in Eastern 
Australia. Journal of Antimicrobial 
Chemotherapy, 70(8), 2413-2414.
[49] Lahiri, S. D., McLaughlin, R. E., 
Whiteaker, J. D., Ambler, J. E., & Alm, 
R. A. (2015). Molecular characterization 
of MRSA isolates bracketing the current 
EUCAST ceftaroline-susceptible 
breakpoint for Staphylococcus aureus: 
the role of PBP2a in the activity of 
ceftaroline. Journal of Antimicrobial 
Chemotherapy, 70(9), 2488-2498.
[50] Chan, L. C., Basuino, L., Diep, B., 
Hamilton, S., Chatterjee, S. S., & 
Chambers, H. F. (2015). Ceftobiprole-
and ceftaroline-resistant methicillin-
resistant Staphylococcus aureus. 
Antimicrobial agents and 
chemotherapy, 59(5), 2960-2963.
[51] Lahiri, S. D., & Alm, R. A. (2016). 
Potential of Staphylococcus aureus 
isolates carrying different PBP2a alleles 
to develop resistance to ceftaroline. 
Journal of Antimicrobial Chemotherapy, 
71(1), 34-40.
[52] Sarkar, P., & Haldar, J. (2019). 
Glycopeptide Antibiotics: Mechanism of 
Action and Recent Developments. 
Antibiotic Drug Resistance, 73-95.
[53] Lin, L. C., Chang, S. C., Ge, M. C., 
Liu, T. P., & Lu, J. J. (2018). Novel 
single-nucleotide variations associated 
with vancomycin resistance in 
vancomycin-intermediate 
Staphylococcus aureus. Infection and 
drug resistance, 11, 113.
[54] Tan, X. E., Neoh, H. M., Looi, M. 
L., Chin, S. F., Cui, L., Hiramatsu, K., 
Hussin, S., & Jamal, R. (2017). 
Activated ADI pathway: the initiator of 
intermediate vancomycin resistance in 
Staphylococcus aureus. Canadian 
journal of microbiology, 63(3), 
260-264.
[55] Werner, G., Strommenger, B., & 
Witte, W. (2008). Acquired vancomycin 
resistance in clinically relevant 
pathogens.
[56] Gomes, D. M., Ward, K. E., & 
LaPlante, K. L. (2015). Clinical 
Implications of Vancomycin 
Heteroresistant and Intermediately 
Susceptible Staphylococcus aureus. 
Pharmacotherapy: The Journal of 
Human Pharmacology and Drug 
Therapy, 35(4), 424-432.
[57] Chen, H., Xiong, Z., Liu, K., Li, S., 
Wang, R., Wang, X., ... & Wang, H. 
(2016). Transcriptional profiling of the 
two-component regulatory system 
VraSR in Staphylococcus aureus with 
low-level vancomycin resistance. 
International journal of antimicrobial 
agents, 47(5), 362-367.
[58] Katayama, Y., Sekine, M., 
Hishinuma, T., Aiba, Y., & Hiramatsu, 
K. (2016). Complete reconstitution of 
the vancomycin-intermediate 
Staphylococcus aureus phenotype of 
strain Mu50 in vancomycin-susceptible 




[59] Yoo, J. I., Kim, J. W., Kang, G. S., 
Kim, H. S., Yoo, J. S., & Lee, Y. S. (2013). 
Prevalence of amino acid changes in the 
yvqF, vraSR, graSR, and tcaRAB genes 
from vancomycin intermediate resistant 
Staphylococcus aureus. Journal of 
microbiology, 51(2), 160-165.
[60] Hollenbeck, B. L., & Rice, L. B. 
(2012). Intrinsic and acquired resistance 
mechanisms in enterococcus. Virulence, 
3(5), 421-569.
[61] Humphries, R. M., Pollett, S., & 
Sakoulas, G. (2013). A current 
perspective on daptomycin for the 
clinical microbiologist. Clinical 
microbiology reviews, 26(4),  
759-780.
[62] Murthy, M. H., Olson, M. E., 
Wickert, R. W., Fey, P. D., & Jalali, Z. 
(2008). Daptomycin non-susceptible 
meticillin-resistant Staphylococcus 
aureus USA 300 isolate. Journal of 
medical microbiology, 57(8), 
1036-1038.
[63] Mammina, C., Bonura, C., di Carlo, 
P., Calà, C., Aleo, A., Monastero, R., & 
Palma, D. M. (2010). Daptomycin 
non-susceptible, vancomycin 
intermediate methicillin-resistant 
Staphylococcus aureus ST398 from a 
chronic leg ulcer, Italy. Scandinavian 
journal of infectious diseases, 42(11-
12), 955-957.
[64] Silverman, J. A., Oliver, N., Andrew, 
T., & Li, T. (2001). Resistance studies 
with daptomycin. Antimicrobial Agents 
and Chemotherapy, 45(6), 1799-1802.
[65] Jones, T., Yeaman, M. R., Sakoulas, 
G., Yang, S. J., Proctor, R. A., Sahl, H.G., 
Schrenzel, J., Xiong, Y.Q. , & Bayer, A. 
S. (2008). Failures in clinical treatment 
of Staphylococcus aureus infection with 
daptomycin are associated with 
alterations in surface charge, membrane 
phospholipid asymmetry, and drug 
binding. Antimicrobial agents and 
chemotherapy, 52(1), 269-278.
[66] Bellido, J. L. M. (2017). Mechanisms 
of resistance to daptomycin in 
Staphylococcus aureus. Rev. Esp. 
Quimioter, 30, 391-396.
[67] Mishra, N. N., Yang, S. J., Sawa, A., 
Rubio, A., Nast, C. C., Yeaman, M. R., 
& Bayer, A. S. (2009). Analysis of cell 
membrane characteristics of in vitro-
selected daptomycin-resistant strains of 
methicillin-resistant Staphylococcus 
aureus. Antimicrobial agents and 
chemotherapy, 53(6), 2312-2318.
[68] Ernst, C. M., Slavetinsky, C. J., 
Kuhn, S., Hauser, J. N., Nega, M., 
Mishra, N. N., Gekeler, C., Bayer, A.S., 
& Peschel, A. (2018). Gain-of-function 
mutations in the phospholipid flippase 
MprF confer specific daptomycin 
resistance. MBio, 9(6).
[69] Roch, M., Gagetti, P., Davis, J., 
Ceriana, P., Errecalde, L., Corso, A., & 
Rosato, A. E. (2017). Daptomycin 
resistance in clinical MRSA strains is 
associated with a high biological fitness 
cost. Frontiers in microbiology, 8, 2303.
[70] Barros, E. M., Martin, M. J., Selleck, 
E. M., Lebreton, F., Sampaio, J. L. M., & 
Gilmore, M. S. (2019). Daptomycin 
resistance and tolerance due to loss of 
function in Staphylococcus aureus dsp1 
and asp23. Antimicrobial agents and 
chemotherapy, 63(1).
[71] Sabat, A. J., Tinelli, M., 
Grundmann, H., Akkerboom, V., 
Monaco, M., Del Grosso, M., Errico, G., 
Pantosti, A., & Friedrich, A. W. (2018). 
Daptomycin resistant Staphylococcus 
aureus clinical strain with novel non-
synonymous mutations in the mprF and 
vraS genes: a new insight into 
daptomycin resistance. Frontiers in 
microbiology, 9, 2705.
[72] Kanesaka, I., Fujisaki, S., Aiba, Y., 
Watanabe, S., Mikawa, T., Katsuse, A. 
K., Takahashi, H., Cui, L., & Kobayashi, 
I. (2019). Characterization of 
compensatory mutations associated 
17
Mechanistic Insights of Drug Resistance in Staphylococcus Aureus with Special Reference to Newer…
DOI: http://dx.doi.org/10.5772/intechopen.100045
with restoration of daptomycin-
susceptibility in daptomycin non-
susceptible methicillin-resistant 
Staphylococcus aureus and the role 
mprF mutations. Journal of Infection 
and Chemotherapy, 25(1), 1-5.
[73] Vakulenko, S. B., & Mobashery, S. 
(2003). Versatility of aminoglycosides 
and prospects for their future. Clinical 
microbiology reviews, 16(3), 430-450.
[74] Ramirez, M. S., & Tolmasky, M. E. 
(2010). Aminoglycoside modifying 
enzymes. Drug resistance updates, 
13(6), 151-171.
[75] Krause, K. M., Serio, A. W.,  
Kane, T. R., & Connolly, L. E. (2016). 
Aminoglycosides: an overview. Cold 
Spring Harbor perspectives in medicine, 
6(6), a027029.
[76] Díaz, M. C. L., Ríos, E., Rodríguez-
Avial, I., Simaluiza, R. J., Picazo, J. J., & 
Culebras, E. (2017). In-vitro activity of 
several antimicrobial agents against 
methicillin-resistant Staphylococcus 
aureus (MRSA) isolates expressing 
aminoglycoside-modifying enzymes: 
potency of plazomicin alone and in 
combination with other agents. 
International journal of antimicrobial 
agents, 50(2), 191-196.
[77] Shaeer, K. M., Zmarlicka, M. T., 
Chahine, E. B., Piccicacco, N., & Cho, J. 
C. (2019). Plazomicin: A Next-
Generation Aminoglycoside. 
Pharmacotherapy: The Journal of 
Human Pharmacology and Drug 
Therapy, 39(1), 77-93.
[78] Rybak, J. M., & Roberts, K. (2015). 
Tedizolid phosphate: a next-generation 
oxazolidinone. Infectious diseases and 
therapy, 4(1), 1-14.
[79] Munita, J. M., Bayer, A. S., & Arias, 
C. A. (2015). Evolving resistance among 
Gram-positive pathogens. Clinical 
Infectious Diseases, 61(suppl_2), 
S48-S57.
[80] Pillai, S. K., Sakoulas, G., 
Wennersten, C., Eliopoulos, G. M., 
Moellering Jr, R. C., Ferraro, M. J., & 
Gold, H. S. (2002). Linezolid resistance 
in Staphylococcus aureus: 
characterization and stability of 
resistant phenotype. The Journal of 
infectious diseases, 186(11), 1603-1607.
[81] Livermore, D. M. (2003). Linezolid 
in vitro: mechanism and antibacterial 
spectrum. Journal of Antimicrobial 
Chemotherapy, 51(suppl_2), ii9-ii16.
[82] Belousoff, M. J., Eyal, Z., Radjainia, 
M., Ahmed, T., Bamert, R. S., Matzov, 
D., Bashan, A., Zimmerman, E., Mishra, 
S., Cameron, D., & Yonath, A. (2017). 
Structural basis for linezolid binding 
site rearrangement in the 
Staphylococcus aureus ribosome. 
MBio, 8(3).
[83] Gu, B., Kelesidis, T., Tsiodras, S., 
Hindler, J., & Humphries, R. M. (2013). 
The emerging problem of linezolid-
resistant Staphylococcus. Journal of 
Antimicrobial Chemotherapy, 
68(1), 4-11.
[84] Li, S. M., Zhou, Y. F., Li, L., Fang, L. 
X., Duan, J. H., Liu, F. R., Liang, H.Q., 
Wu, Y.T., Gu, W.Q., Liao, X.P., & Liu, Y. 
H. (2018). Characterization of the 
multi-drug resistance gene cfr in 
methicillin-resistant Staphylococcus 
aureus (MRSA) strains isolated from 
animals and humans in China. Frontiers 
in microbiology, 9, 2925.
[85] Wang, Y., Lv, Y., Cai, J., Schwarz, S., 
Cui, L., Hu, Z., Zhang, R., Li, J., Zhao, 
Q., He, T., & Shen, J. (2015). A novel 
gene, optrA, that confers transferable 
resistance to oxazolidinones and 
phenicols and its presence in 
Enterococcus faecalis and Enterococcus 
faecium of human and animal origin. 
Journal of Antimicrobial Chemotherapy, 
70(8), 2182-2190.
[86] Foster, T. J. (2017). Antibiotic 
resistance in Staphylococcus aureus. 
Staphylococcus aureus
18
Current status and future prospects. 
FEMS microbiology reviews, 41(3), 
430-449.
[87] Wang, Y., Li, X., Wang, Y., Schwarz, 
S., Shen, J., & Xia, X. (2018). 
Intracellular accumulation of linezolid 
and florfenicol in OptrA-producing 
Enterococcus faecalis and Staphylococcus 
aureus. Molecules, 23(12), 3195.
[88] Sharkey, L. K., Edwards, T. A., & 
O’Neill, A. J. (2016). ABC-F proteins 
mediate antibiotic resistance through 
ribosomal protection. MBio, 7(2).
[89] Antonelli, A., D’Andrea, M. M., 
Brenciani, A., Galeotti, C. L.,  
Morroni, G., Pollini, S., Varaldo, P.E., & 
Rossolini, G. M. (2018). 
Characterization of poxtA, a novel 
phenicol–oxazolidinone–tetracycline 
resistance gene from an MRSA of 
clinical origin. Journal of Antimicrobial 
Chemotherapy, 73(7), 1763-1769.
[90] Saravolatz, L. D., & Stein, G. E. 
(2019). Delafloxacin: A New Anti–
methicillin-resistant Staphylococcus 
aureus Fluoroquinolone. Clinical 
Infectious Diseases, 68(6), 1058-1062.
[91] Lemaire, S., Tulkens, P. M., & Van 
Bambeke, F. (2011). Contrasting effects 
of acidic pH on the extracellular and 
intracellular activities of the anti-gram-
positive fluoroquinolones moxifloxacin 
and delafloxacin against Staphylococcus 
aureus. Antimicrobial agents and 
chemotherapy, 55(2), 649-658.
[92] Van Bambeke, F. (2015). 
Delafloxacin, a non-zwitterionic 
fluoroquinolone in phase III of clinical 
development: evaluation of its 
pharmacology, pharmacokinetics, 
pharmacodynamics and clinical 
efficacy. Future microbiology, 10(7), 
1111-1123.
[93] Bauer, J., Siala, W., Tulkens, P. M., 
& Van Bambeke, F. (2013). A combined 
pharmacodynamic quantitative and 
qualitative model reveals the potent 
activity of daptomycin and delafloxacin 
against Staphylococcus aureus biofilms. 
Antimicrobial agents and 
chemotherapy, 57(6), 2726-2737.
[94] Siala, W., Mingeot-Leclercq, M. P., 
Tulkens, P. M., Hallin, M., Denis, O., & 
Van Bambeke, F. (2014). Comparison of 
the antibiotic activities of daptomycin, 
vancomycin, and the investigational 
fluoroquinolone delafloxacin against 
biofilms from Staphylococcus aureus 
clinical isolates. Antimicrobial agents 
and chemotherapy, 58(11), 6385-6397.
[95] Wassenaar, T., Ussery, D., Nielsen, 
L., & Ingmer, H. (2015). Review and 
phylogenetic analysis of qac genes that 
reduce susceptibility to quaternary 
ammonium compounds in 
Staphylococcus species. European 
Journal of Microbiology and 
Immunology, 5(1), 44-61.
[96] Costa, S. S., Falcão, C., Viveiros, M., 
Machado, D., Martins, M., Melo-
Cristino, J., Amaral, L., & Couto, I. 
(2011). Exploring the contribution of 
efflux on the resistance to 
fluoroquinolones in clinical isolates of 
Staphylococcus aureus. BMC 
microbiology, 11(1), 1-12.
[97] Muñoz-Bellido, J. L., Manzanares, 
M. A., Andrés, J. M., Zufiaurre, M. G., 
Ortiz, G., Hernández, M. S., & García-
Rodríguez, J. A. (1999). Efflux pump-
mediated quinolone resistance in 
Staphylococcus aureus strains wild type 
for gyrA, gyrB, grlA, and norA. 
Antimicrobial agents and 
chemotherapy, 43(2), 354-356.
[98] Remy, J. M., Tow-Keogh, C. A., 
McConnell, T. S., Dalton, J. M., & 
DeVito, J. A. (2012). Activity of 
delafloxacin against methicillin-
resistant Staphylococcus aureus: 
resistance selection and 
characterization. Journal of 
antimicrobial chemotherapy, 67(12), 
2814-2820.
19
Mechanistic Insights of Drug Resistance in Staphylococcus Aureus with Special Reference to Newer…
DOI: http://dx.doi.org/10.5772/intechopen.100045
[99] Greer, E. L., Banko, M. R., & 
Brunet, A. (2009). AMP-activated 
protein kinase and FoxO transcription 
factors in dietary restriction–induced 
longevity. Annals of the New York 
Academy of Sciences, 1170, 688.
[100] Prince, W. T., Ivezic-Schoenfeld, 
Z., Lell, C., Tack, K. J., Novak, R., 
Obermayr, F., & Talbot, G. H. (2013). 
Phase II clinical study of BC-3781, a 
pleuromutilin antibiotic, in treatment of 
patients with acute bacterial skin and 
skin structure infections. Antimicrobial 
agents and chemotherapy, 57(5), 
2087-2094.
[101] Paukner, S., & Riedl, R. (2017). 
Pleuromutilins: potent drugs for 
resistant bugs—mode of action and 
resistance. Cold Spring Harbor 
perspectives in medicine, 7(1), a027110.
[102] Schwarz, S., Shen, J., Kadlec, K., 
Wang, Y., Michael, G. B., Feßler, A. T., 
& Vester, B. (2016). Lincosamides, 
streptogramins, phenicols, and 
pleuromutilins: mode of action and 
mechanisms of resistance. Cold Spring 
Harbor perspectives in medicine, 6(11), 
a027037.
[103] Gentry, D. R., Rittenhouse, S. F., 
McCloskey, L., & Holmes, D. J. (2007). 
Stepwise exposure of Staphylococcus 
aureus to pleuromutilins is associated 
with stepwise acquisition of mutations 
in rplC and minimally affects 
susceptibility to retapamulin. 
Antimicrobial agents and 
chemotherapy, 51(6), 2048-2052.
[104] Kehrenberg, C., Schwarz, S., 
Jacobsen, L., Hansen, L. H., & Vester, B. 
(2005). A new mechanism for 
chloramphenicol, florfenicol and 
clindamycin resistance: methylation of 
23S ribosomal RNA at A2503. Molecular 
microbiology, 57(4), 1064-1073.
[105] Van Duijkeren, E., Greko, C., 
Pringle, M., Baptiste, K. E., Catry, B., 
Jukes, H., Moreno, M.A., Pomba, 
M.C.M.F., Pyörälä, S., Rantala, M., & 
Törneke, K. (2014). Pleuromutilins: use 
in food-producing animals in the 
European Union, development of 
resistance and impact on human and 
animal health. Journal of Antimicrobial 
Chemotherapy, 69(8), 2022-2031.
[106] Mendes, R. E., Paukner, S., Doyle, 
T. B., Gelone, S. P., Flamm, R. K., & 
Sader, H. S. (2019). Low prevalence of 
gram-positive isolates showing elevated 
lefamulin MIC results during the 
SENTRY surveillance program for 
2015-2016 and characterization of 
resistance mechanisms. Antimicrobial 
agents and chemotherapy, 63(4).
[107] Kadlec, K., & Schwarz, S. (2009). 
Novel ABC transporter gene, vga (C), 
located on a multiresistance plasmid 
from a porcine methicillin-resistant 
Staphylococcus aureus ST398 strain. 
Antimicrobial agents and 
chemotherapy, 53(8), 3589-3591.
[108] Miller, M. A., Dascal, A., Portnoy, 
J., & Mendelson, J. (1996). 
Development of mupirocin resistance 
among methicillin-resistant 
Staphylococcus aureus after widespread 
use of nasal mupirocin ointment. 
Infection Control & Hospital 
Epidemiology, 17(12), 811-813.
[109] Vasquez, J. E., Walker, E. S., 
Franzus, B. W., Overbay, B. K., Reagan, 
D. R., & Sarubbi, F. A. (2000). The 
epidemiology of mupirocin resistance 
among methicillin-resistant 
Staphylococcus aureus at a Veterans' 
Affairs hospital. Infection Control & 
Hospital Epidemiology, 21(7), 459-464.
[110] de Castro Nunes, E. L., dos Santos, 
K. R. N., Mondino, P. J. J., de Freire 
Bastos, M. D. C., & Giambiagi-
deMarval, M. (1999). Detection of 
ileS-2 gene encoding mupirocin 
resistance in methicillin-resistant 
Staphylococcus aureus by multiplex 
PCR. Diagnostic microbiology and 
infectious disease, 34(2), 77-81.
Staphylococcus aureus
20
[111] Patel, J. B., Gorwitz, R. J., & 
Jernigan, J. A. (2009). Mupirocin 
resistance. Clinical infectious diseases, 
49(6), 935-941.
[112] Hayden, M. K., Lolans, K., 
Haffenreffer, K., Avery, T. R., Kleinman, 
K., Li, H., Kaganov, R.E., Lankiewicz, J., 
Moody, J., Septimus, E., & Huang, S. S. 
(2016). Chlorhexidine and mupirocin 
susceptibility of methicillin-resistant 
Staphylococcus aureus isolates in the 
REDUCE-MRSA trial. Journal of clinical 
microbiology, 54(11), 2735-2742.
[113] Lounsbury, N., Eidem, T., 
Colquhoun, J., Mateo, G., Abou-
Gharbia, M., Dunman, P. M., & 
Childers, W. E. (2018). Novel inhibitors 
of Staphylococcus aureus RnpA that 
synergize with mupirocin. Bioorganic & 
medicinal chemistry letters, 28(6), 
1127-1131.
[114] Zhanel, G. G., Calic, D., & 
Schweizer, F. (2010). Dalbavancin, 
oritavancin and telavancin: a 
comparative review. Drugs, 70, 
859-886.
[115] Zeng, D., Debabov, D., Hartsell, T. 
L., Cano, R. J., Adams, S., Schuyler, J. 
A., McMillan, R., & Pace, J. L. (2016). 
Approved glycopeptide antibacterial 
drugs: mechanism of action and 
resistance. Cold Spring Harbor 
perspectives in medicine, 6(12), 
a026989.
[116] McCurdy, S. P., Jones, R. N., 
Mendes, R. E., Puttagunta, S., & 
Dunne, M. W. (2015). In vitro activity 
of dalbavancin against drug-resistant 
Staphylococcus aureus isolates from a 
global surveillance program. 
Antimicrobial agents and 
chemotherapy, 59(8), 5007-5009.
[117] Duncan, L. R., Sader, H. S., Smart, 
J. I., Flamm, R. K., & Mendes, R. E. 
(2017). Telavancin activity in vitro 
tested against a worldwide collection of 
Gram-positive clinical isolates (2014). 
Journal of global antimicrobial 
resistance, 10, 271-276.
[118] Kussmann, M., Karer, M., 
Obermueller, M., Schmidt, K., 
Barousch, W., Moser, D., Nehr, M., 
Ramharter, M., Poeppl, W., 
Makristathis, A., & Lagler, H. (2018). 
Emergence of a dalbavancin induced 
glycopeptide/lipoglycopeptide non-
susceptible Staphylococcus aureus 
during treatment of a cardiac device-
related endocarditis. Emerging microbes 
& infections, 7(1), 1-10.
[119] Werth, B. J., Jain, R., Hahn, A., 
Cummings, L., Weaver, T., Waalkes, A., 
Sengupta, D., Salipante, S.J., Rakita, 
R.M., & Butler-Wu, S. M. (2018). 
Emergence of dalbavancin non-
susceptible, vancomycin-intermediate 
Staphylococcus aureus (VISA) after 
treatment of MRSA central line-
associated bloodstream infection with a 
dalbavancin-and vancomycin-
containing regimen. Clinical 
Microbiology and Infection, 24(4), 429.
e1-429.e5.
[120] Fleming, A. (2001). On the 
antibacterial action of cultures of a 
penicillium, with special reference to 
their use in the isolation of B. 
influenzae. Bulletin of the World Health 
Organization, 79, 780-790.
[121] Lederberg, J. (1957). Mechanism of 
action of penicillin. Journal of 
bacteriology, 73(1), 144.
[122] Lowy, F. D. (2003). Antimicrobial 
resistance: the example of 
Staphylococcus aureus. The Journal of 
clinical investigation, 111(9), 1265-1273.
[123] Kirby, W. M. (1944). Extraction of 
a highly potent penicillin inactivator 
from penicillin resistant staphylococci. 
Science, 99(2579), 452-453.
[124] Rammelkamp, C. H., & Maxon, T. 
(1942). Resistance of Staphylococcus 
aureus to the Action of Penicillin. 
21
Mechanistic Insights of Drug Resistance in Staphylococcus Aureus with Special Reference to Newer…
DOI: http://dx.doi.org/10.5772/intechopen.100045
Proceedings of the Society for 
Experimental Biology and Medicine, 
51(3), 386-389.
[125] Bondi Jr, A., & Dietz, C. C. (1945). 
Penicillin resistant staphylococci. 
Proceedings of the Society for 
Experimental Biology and Medicine, 
60(1), 55-58.
[126] Smith, I. M., & Vickers, A. B. 
(1960). Natural History of 338 Treated 
and Untreated Patients with 
Staphylococcal septicaemia (1936-
1955.). Lancet, 1318-22.
[127] Jessen, O., Rosendal, K., Bülow, P., 
Faber, V., & Eriksen, K. R. (1969). 
Changing staphylococci and 
staphylococcal infections: a ten-year 
study of bacteria and cases of 
bacteremia. New England Journal of 
Medicine, 281(12), 627-635.
[128] Jevons, M. P. (1961). “Celbenin”-
resistant staphylococci. British medical 
journal, 1(5219), 124.
[129] Katayama, Y., Ito, T., & Hiramatsu, 
K. (2000). A new class of genetic 
element, staphylococcus cassette 
chromosome mec, encodes methicillin 
resistance in Staphylococcus aureus. 
Antimicrobial agents and chemo 
therapy, 44(6), 1549-1555.
[130] Hiramatsu, K., Asada, K., Suzuki, 
E., Okonogi, K., & Yokota, T. (1992). 
Molecular cloning and nucleotide 
sequence determination of the regulator 
region of mecA gene in methicillin-
resistant Staphylococcus aureus 
(MRSA). FEBS letters, 298(2-3), 
133-136.
[131] Hartman, B. J., & Tomasz, A. 
(1984). Low-affinity penicillin-binding 
protein associated with beta-lactam 
resistance in Staphylococcus aureus. 
Journal of bacteriology, 158(2), 513-516.
[132] Reynolds, P. E., & Brown, D. F. 
(1985). Penicillin-binding proteins of 
β-lactam-resistant strains of 
Staphylococcus aureus: effect of growth 
conditions. FEBS letters, 192(1), 28-32.
[133] Rountree, P. M., & Beard, M. A. 
(1968). Hospital strains of 
Staphylococcus aureus, with particular 
reference to methicillin-resistant 
strains. Medical Journal of Australia, 
2(26), 1163-8.
[134] Mäkelä, M. J., Puhakka, T., 
Ruuskanen, O., Leinonen, M., Saikku, 
P., Kimpimäki, M., Blomqvist, S., 
Hyypiä, T., & Arstila, P. (1998). Viruses 
and bacteria in the etiology of the 
common cold. Journal of clinical 
microbiology, 36(2), 539-542.
[135] Torvaldsen, S., Roberts, C., & 
Riley, T. V. (1999). The continuing 
evolution of methicillin-resistant 
Staphylococcus aureus in Western 
Australia. Infection control and hospital 
epidemiology, 20(2), 133-135.
[136] Barret, F. F. (1968). Methicillin 
resistant Staphylococcus aureus at 
Boston City Hospital. N Engl J Med, 279, 
441-448.
[137] Panlilio, A. L., Culver, D. H., 
Gaynes, R. P., Banerjee, S., Henderson, 
T. S., Tolson, J. S., Martone, W.J., & 
National Nosocomial Infections 
Surveillance System. (1992). 
Methicillin-resistant Staphylococcus 
aureus in US hospitals, 1975-1991. 
Infection Control & Hospital 
Epidemiology, 13(10), 582-586.
[138] Meyer, E., Schwab, F., Gastmeier, 
P., Jonas, D., Rueden, H., & Daschner, F. 
D. (2006). Methicillin-resistant 
Staphylococcus aureus in German 
intensive care units during 2000-2003: 
data from Project SARI (Surveillance of 
Antimicrobial Use and Antimicrobial 
Resistance in Intensive Care Units). 
Infection Control & Hospital 
Epidemiology, 27(2), 146-154.
[139] Alcoceba, E., Mena, A., Perez, M. 
C., de Gopegui, E. R., Padilla, E., Gil, J., 
Staphylococcus aureus
22
Ramirez, A., Gallegos, C., Serra, A., 
Perez, J.L., & Oliver, A. (2007). 
Molecular epidemiology of methicillin-
resistant Staphylococcus aureus in 
Majorcan hospitals: high prevalence of 
the epidemic clone EMRSA-15. Clinical 
microbiology and infection, 13(6), 
599-605.
[140] Conceicao, T., Aires-de-Sousa, M., 
Füzi, M., Toth, A., Paszti, J., Ungvári, 
E., ... & De Lencastre, H. (2007). 
Replacement of methicillin-resistant 
Staphylococcus aureus clones in 
Hungary over time: a 10-year 
surveillance study. Clinical 
Microbiology and Infection, 13(10), 
971-979.
[141] Durmaz, B., Durmaz, R., & Şahin, 
K. (1997). Methicillin-resistance among 
Turkish isolates of Staphylococcus 
aureus strains from nosocomial and 
community infections and their 
resistance patterns using various 
antimicrobial agents. Journal of Hospital 
Infection, 37(4), 325-329.
[142] Peng, Q., Hou, B., Zhou, S., Huang, 
Y., Hua, D., Yao, F., & shu Qian, Y. 
(2010). Staphylococcal cassette 
chromosome mec (SCCmec) analysis 
and antimicrobial susceptibility profiles 
of methicillin-resistant Staphylococcus 
aureus (MRSA) isolates in a teaching 
hospital, Shantou, China. African 
Journal of Microbiology Research, 4(9), 
844-848.
[143] Fluit, A. C., Wielders, C. L. C., 
Verhoef, J., & Schmitz, F. J. (2001). 
Epidemiology and susceptibility of 
3,051 Staphylococcus aureus isolates 
from 25 university hospitals 
participating in the European SENTRY 
study. Journal of clinical microbiology, 
39(10), 3727-3732.
[144] Lin, Y. C., Lauderdale, T. L., Lin, 
H. M., Chen, P. C., Cheng, M. F., Hsieh, 
K. S., & Liu, Y. C. (2007). An outbreak 
of methicillin-resistant Staphylococcus 
aureus infection in patients of a 
pediatric intensive care unit and high 
carriage rate among health care workers. 
Journal of Microbiology, Immunology, 
and Infection, 40(4), 325-334.
[145] Manzur, A., Dominguez, A. M., 
Pujol, M., González, M. P. M., Limon, 
E., Hornero, A., Martín, R., Gudiol, F., 
& Ariza, J. (2008). Community-acquired 
methicillin-resistant Staphylococcus 
aureus infections: an emerging threat in 
Spain. Clinical Microbiology and 
Infection, 14(4), 377-380.
[146] Oteo, J., Baquero, F., Vindel, A., & 
Campos, J. (2004). Antibiotic resistance 
in 3113 blood isolates of Staphylococcus 
aureus in 40 Spanish hospitals 
participating in the European 
Antimicrobial Resistance Surveillance 
System (2000-2002). Journal of 
Antimicrobial Chemotherapy, 53(6), 
1033-1038.
[147] Tiemersma, E. W., Bronzwaer, S. 
L., Lyytikäinen, O., Degener, J. E., 
Schrijnemakers, P., Bruinsma, N., 
Monen, J., Witte, W., Grundmann, H., 
& European Antimicrobial Resistance 
Surveillance System Participants. 
(2004). Methicillin-resistant 
Staphylococcus aureus in Europe, 
1999-2002. Emerging infectious 
diseases, 10(9), 1627.
[148] Kayaba, H., Kodama, K., Tamura, 
H., & Fuhwara, Y. (1997). The spread of 
methicillin-resistant Staphylococcus 
aureus in a rural community: will it 
become a common microorganism 
colonizing among the general 
population?. Surgery today, 27(3), 
217-219.
[149] Piao, C., Karasawa, T., Totsuka, K., 
Uchiyama, T., & Kikuchi, K. (2005). 
Prospective surveillance of community-
onset and healthcare-associated 
methicillin-resistant Staphylococcus 
aureus isolated from a university-
affiliated hospital in Japan. 
Microbiology and immunology, 49(11), 
959-970.
23
Mechanistic Insights of Drug Resistance in Staphylococcus Aureus with Special Reference to Newer…
DOI: http://dx.doi.org/10.5772/intechopen.100045
[150] Udo, E. E., Pearman, J. W., & 
Grubb, W. B. (1993). Genetic analysis of 
community isolates of methicillin-
resistant Staphylococcus aureus in 
Western Australia. Journal of Hospital 
Infection, 25(2), 97-108.
[151] Ito, T., Iijima, M., Fukushima, T., 
Nonoyama, M., Ishii, M., Baranovich, 
T., Otsuka, T., Takano, T., & Yamamoto, 
T. (2008). Pediatric pneumonia death 
caused by community-acquired 
methicillin-resistant Staphylococcus 
aureus, Japan. Emerging infectious 
diseases, 14(8), 1312.
[152] Takizawa, Y., Taneike, I., 
Nakagawa, S., Oishi, T., Nitahara, Y., 
Iwakura, N., Ozaki, K., Takano, M., 
Nakayama, T., & Yamamoto, T. (2005). 
A Panton-Valentine leucocidin (PVL)-
positive community-acquired 
methicillin-resistant Staphylococcus 
aureus (MRSA) strain, another such 
strain carrying a multiple-drug 
resistance plasmid, and other more-
typical PVL-negative MRSA strains 
found in Japan. Journal of clinical 
microbiology, 43(7), 3356-3363.
[153] Kerttula, A. M., Lyytikäinen, O., 
Kardén-Lilja, M., Ibrahem, S., 
Salmenlinna, S., Virolainen, A., & 
Vuopio-Varkila, J. (2007). Nationwide 
trends in molecular epidemiology of 
methicillin-resistant Staphylococcus 
aureus, Finland, 1997-2004. BMC 
Infectious Diseases, 7(1), 1-9.
[154] Andersen, B. M., Rasch, M., & 
Syversen, G. (2007). Is an increase of 
MRSA in Oslo, Norway, associated with 
changed infection control policy?. 
Journal of Infection, 55(6), 531-538.
[155] Skov, R., Gudlaugsson, O., 
Hardardottir, H., Harthug, S., Jakobsen, 
T., Jørn Kolmos, H., Olsson-Liljequist, 
B., Peltonen, R., Tveten, Y., Vuopio-
Varkila, J., & Åhrén, C. (2008). 
Proposal for common Nordic 
epidemiological terms and definitions 
for methicillin-resistant Staphylococcus 
aureus (MRSA). Scandinavian journal 
of infectious diseases, 40(6-7), 495-502.
[156] Stenhem, M., Örtqvist, Å., 
Ringberg, H., Larsson, L., Olsson-
Liljequist, B., Hæggman, S., & Ekdahl, 
K. (2006). Epidemiology of methicillin-
resistant Staphylococcus aureus (MRSA) 
in Sweden 2000-2003, increasing 
incidence and regional differences. 
BMC Infectious Diseases, 6(1), 1-7.
[157] Nimmo, G. R., Fong, J., Paterson, 
D. L., & McLaws, M. L. (2008). 
Changing epidemiology of meticillin-
resistant S. aureus in Queensland, 
Australia, 2000-2006: use of passive 
surveillance of susceptibility 
phenotypes. Journal of Hospital 
Infection, 70(4), 305-313.
[158] Song, J. H., Hsueh, P. R., Chung, D. 
R., Ko, K. S., Kang, C. I., Peck, K. R., 
Yeom, J.S., Kim, S.W., Chang, H.H., 
Kim, Y.S., & Carlos, C. C. (2011). 
Spread of methicillin-resistant 
Staphylococcus aureus between the 
community and the hospitals in Asian 
countries: an ANSORP study. Journal of 
antimicrobial chemotherapy, 66(5), 
1061-1069.
